ZA878183B - Ifosphamide lyophilisate and process for its preparation - Google Patents

Ifosphamide lyophilisate and process for its preparation

Info

Publication number
ZA878183B
ZA878183B ZA878183A ZA878183A ZA878183B ZA 878183 B ZA878183 B ZA 878183B ZA 878183 A ZA878183 A ZA 878183A ZA 878183 A ZA878183 A ZA 878183A ZA 878183 B ZA878183 B ZA 878183B
Authority
ZA
South Africa
Prior art keywords
ifosphamide
lyophilisate
preparation
ifosfamide
weight
Prior art date
Application number
ZA878183A
Other languages
English (en)
Inventor
Sauerbier Dieter
Dammann Uwe-Peter
Isaac Otto
Original Assignee
Asta Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Aktiengesellschaft filed Critical Asta Pharma Aktiengesellschaft
Publication of ZA878183B publication Critical patent/ZA878183B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Indole Compounds (AREA)
  • Amplifiers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Control Of El Displays (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA878183A 1986-10-31 1987-10-30 Ifosphamide lyophilisate and process for its preparation ZA878183B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31

Publications (1)

Publication Number Publication Date
ZA878183B true ZA878183B (en) 1988-05-02

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA878183A ZA878183B (en) 1986-10-31 1987-10-30 Ifosphamide lyophilisate and process for its preparation

Country Status (25)

Country Link
EP (1) EP0265812B1 (cs)
JP (1) JPS63159319A (cs)
KR (1) KR900003491B1 (cs)
AT (1) ATE55250T1 (cs)
AU (1) AU598602B2 (cs)
CA (1) CA1314231C (cs)
DD (1) DD262582A5 (cs)
DE (1) DE3764235D1 (cs)
DK (1) DK169308B1 (cs)
EG (1) EG18333A (cs)
ES (1) ES2017982B3 (cs)
FI (1) FI87140C (cs)
GE (1) GEP19971025B (cs)
GR (1) GR3000708T3 (cs)
HU (1) HU197987B (cs)
IL (1) IL84312A (cs)
IN (1) IN168119B (cs)
LV (1) LV10051B (cs)
MX (1) MX8958A (cs)
NO (1) NO873860L (cs)
PT (1) PT86032B (cs)
RU (1) RU1836079C (cs)
UA (1) UA11075A (cs)
YU (1) YU197387A (cs)
ZA (1) ZA878183B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE65402T1 (de) * 1988-03-19 1991-08-15 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
ID27487A (id) * 1998-03-03 2001-04-12 Shionolog & Co Ltd Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat
BR0314068A (pt) * 2002-09-05 2005-07-05 Bharat Serums & Vaccines Ltd Processo para a preparação de uma composição estável com baixo nìvel de toxicidade; composição estável que contém oxazafosforina; uso de uma composição estável que contém oxazafosforina; e método de tratamento de uma doença maligna
EP1569663B1 (en) * 2002-12-02 2010-04-28 Bharat Serums & Vaccines Ltd. Ifosfamide compositions for parenteral administration and a process for their preparation
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
RU2470623C2 (ru) * 2006-09-29 2012-12-27 Инфа С.А. Упаковка с фармацевтической композицией и комплект для внутривенного введения
CN105900385B (zh) * 2014-12-04 2019-08-27 华为技术有限公司 在数据通信网中的负载分配

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (de) * 1977-05-09 1978-11-16 Walton J Smith Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung
EP0083439B1 (de) * 1981-12-31 1989-07-26 ASTA Pharma AG 4-Sulfido-oxazaphosphorine und deren Verwendung bei der Krebsbekämpfung und zur Immunsuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
UA11075A (uk) 1996-12-25
EP0265812B1 (de) 1990-08-08
ES2017982B3 (es) 1991-03-16
FI874727L (fi) 1988-05-01
PT86032B (pt) 1990-08-31
RU1836079C (ru) 1993-08-23
HUT44932A (en) 1988-05-30
IN168119B (cs) 1991-02-09
FI874727A0 (fi) 1987-10-27
PT86032A (de) 1987-11-01
KR880004814A (ko) 1988-06-27
AU598602B2 (en) 1990-06-28
YU197387A (en) 1988-12-31
MX8958A (es) 1993-12-01
KR900003491B1 (ko) 1990-05-21
DD262582A5 (de) 1988-12-07
GR3000708T3 (en) 1991-10-10
IL84312A0 (en) 1988-03-31
EP0265812A1 (de) 1988-05-04
IL84312A (en) 1991-11-21
FI87140B (fi) 1992-08-31
LV10051A (lv) 1994-05-10
CA1314231C (en) 1993-03-09
AU8052987A (en) 1988-05-05
DK569687D0 (da) 1987-10-30
GEP19971025B (en) 1997-04-06
ATE55250T1 (de) 1990-08-15
NO873860D0 (no) 1987-09-15
HU197987B (en) 1989-07-28
JPS63159319A (ja) 1988-07-02
DK169308B1 (da) 1994-10-10
DK569687A (da) 1988-05-01
EG18333A (en) 1993-12-30
JPH0543684B2 (cs) 1993-07-02
LV10051B (en) 1995-06-20
FI87140C (fi) 1992-12-10
NO873860L (no) 1988-05-02
DE3764235D1 (de) 1990-09-13

Similar Documents

Publication Publication Date Title
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
GR3007251T3 (cs)
EP0348808A3 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung
LU90949I2 (fr) Esters aminoalcohol d'acide thienylcarboxyliques leurs produits quaternaires leur préparation et l'utilisation de ces composés
GR3002377T3 (en) Ifosfamide-mesna-lyophilized composition and process to prepare it
GR850006B (cs)
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
GR3019388T3 (en) The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse
EP0259139A3 (en) Novel pyridinylpyrimidine derivatives, method for production thereof and a plant disease protectant containing them as the active ingredient
ZA878183B (en) Ifosphamide lyophilisate and process for its preparation
ZA882449B (en) Dihydropyridinamides,a process for their preparation,and their use in medicaments
DK23490A (da) Implanteret antibiotisk tilberedning med reguleret frigivelse
ZA894667B (en) Process for the preparation of 2,6-dichlorodiphenyl-amino-acetic derivatives
IL82145A0 (en) Substituted thiacycloalkeno(3,2-b)pyridines,their preparation and pharmaceutical compositions containing them
GR3003638T3 (cs)
KR900700484A (ko) 1,4:3,6-디안히드로 헥시톨 잘산염의 아미노프로판올 유도체,그의 제법 및 약제로서의 그의 용도
CA2022323A1 (en) Excretion of potassium ion by prostanoic acid derivatives
DE3666041D1 (en) Process for preparing 4,5-dihydro-dithienol (3,4b:3'4'-e)-azepin-5,9-dione
IL83495A0 (en) Oxirane pseudooligosaccharides,a process for their preparation,and pharmaceutical preparations containing them
EP0415564A3 (en) Improvement of excretion of nonprotein nitrogen into the intestine by prostanoic acid derivaties
HUT46693A (en) Process for producing dioxabicyclo/3,3,0/oktanon-oxim-ethers and pharmaceutical compositions containing them as active components
AU1732888A (en) Stable 5-fluorouracil compositions
ZA883610B (en) A process for the preparation of 5-acylamino-2,4,6-triiodo-or tribromo-benzioc acid derivatives and the acid derivatives obtained by said process